SCHEMBL886920

SCHEMBL886920

CCCCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.89
KMT2A Q03164 5/20 0.89
MAPT P10636 4/20 0.89
SLC25A20 O43772 3/20 0.89
TP53 P04637 3/20 0.89
TSHR P16473 3/20 0.89
CYP2D6 P10635 2/20 0.89
SLC6A5 Q9Y345 2/20 0.89
CYP2C19 P33261 2/20 0.89
CYP2C9 P11712 2/20 0.89
HIF1A Q16665 2/20 0.89
KDM4E B2RXH2 1/20 0.89
CYP3A4 P08684 1/20 0.89
NFKB1 P19838 1/20 0.89
THPO P40225 1/20 0.89
HSD17B10 Q99714 1/20 0.89
RECQL P46063 1/20 0.71
CYP1A2 P05177 4/20 0.68
MAPK1 P28482 4/20 0.67
GMNN O75496 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288262 1.00 MEN1 (0.89) MEN1KMT2AMAPTSLC25A20TP53
Hydrochloric Acid SCHEMBL28699982 0.98 MEN1 (0.86) MEN1KMT2AMAPTSLC25A20TP53
Hydrochloric Acid SCHEMBL9574613 0.98 MEN1 (0.86) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL235082 0.95 MEN1 (0.97) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL8977796 0.95 MEN1 (0.97) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL9065214 0.94 MEN1 (0.84) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL25373354 0.94 MAPT (1.00) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL17164609 0.94 MAPT (1.00) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL288242 0.94 MAPT (1.00) MEN1KMT2AMAPTSLC25A20TP53
SCHEMBL188470 0.94 MAPT (1.00) MEN1KMT2AMAPTSLC25A20TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115395108-B Preparation method and application of aqueous electrolyte containing quaternary ammonium salt type amphoteric ion additive 中南大学 2024-09-10 CN claimed
CN-117174923-B Graphite felt for enhancing solid-liquid interface interaction and preparation method thereof 杭州德海艾科能源科技有限公司 2024-02-06 CN claimed
CN-117174923-A Graphite felt for enhancing solid-liquid interface interaction and preparation method thereof 杭州德海艾科能源科技有限公司 2023-12-05 CN claimed
US-20230346735-A1 Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal LONZA GREENWOOD LLC 2023-11-02 US claimed
EP-4125858-A1 NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL Lonza Consumer Health Inc. (US) 2023-02-08 EP claimed
CN-115395108-A Preparation method and application of water-based electrolyte containing quaternary ammonium salt type zwitterion additive 中南大学 2022-11-25 CN claimed
CN-113406323-B Latex immunoturbidimetry second reagent, composition containing same and preparation method thereof 上海奥普生物医药股份有限公司 2022-03-22 CN claimed
WO-2021221741-A1 NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL LONZA CONSUMER HEALTH INC. (US) 2021-11-04 WO claimed
CN-113406323-A Latex immunoturbidimetry second reagent, composition containing same and preparation method thereof 上海奥普生物医药股份有限公司 2021-09-17 CN claimed
US-8747906-B2 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2014-06-10 US claimed
WO-2000000183-A2 ANTIOXIDANT, CYTOSTATIC AND SUSTAINED ENERGY COMPOSITION WHICH AMELIORATES THE METABOLIC UTILIZATION OF GLUCOSE COMPRISING ACETYL-L-CARNITINE AND A CATECHIN SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 2000-01-06 WO claimed
WO-1999066914-A2 NEUROPROTECTIVE COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF NERVOUS AND BEHAVIOURAL ALTERATIONS DUE TO ANXIETY STATES OR DEPRESSION, COMPRISING ACETYL-L-CARNITINE AND HYPERICIN SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 1999-12-29 WO claimed
WO-1999066913-A2 COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, COMPRISING PROPIONYL-L-CARNITINE AND GENISTEIN SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 1999-12-29 WO claimed
WO-1999053921-A1 COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND NADH AND/OR NADPH SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) 1999-10-28 WO claimed
WO-1999052517-A2 COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1999-10-21 WO claimed
US-RE36331-E Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1999-10-05 US claimed
EP-0722724-B1 Use of L-carnitine and its derivatives for reducing the toxic effects of cyclosporin-A and others immunosuppressants SIGMA TAU IND FARMACEUTI (IT) 1999-03-24 EP claimed
WO-1999006039-A1 COMPOSITION COMPRISING L-CARNITINE OR AN ALKANOYL L-CARNITINE AND LONG-CHAIN ALKANOLS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1999-02-11 WO claimed
WO-1999001126-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1999-01-14 WO claimed
US-5496821-A Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1996-03-05 US claimed